City File: SmithKline Beecham

Saturday 16 October 1993 23:02 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

THE third-quarter figures from SmithKline Beecham, out on Tuesday, might look dull in comparison with the sparkling figures this time last year, but don't be fooled. SKB is in rude health thanks to the relatively low cost for drugs such as Tagamet, the off-patent ulcer treatment. The group has to be one of the world's greatest marketeers, and is selling its way to pounds 1.22bn of taxable profits this year and pounds 1.35bn next. Its shares, depressed by the possibility it was going to be thrown out of the FT-SE 100, have missed the stock market party and look a snip.

(Graph omitted)

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

City File: SmithKline Beecham

Join our commenting forum

Thank you for registering